pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,348 catalysts · 4,728 grant · 3,350 8k filing · 2,620 approval · 2,108 device 510k · 1,692 device recall · 1,464 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 0 catalysts2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: grant×type: approval×from 2025-08-14×clear all
type
  • grant4,728
  • 8k filing3,350
  • approval2,620
  • device 510k2,108
  • device recall1,692
  • device pma1,464
device adverse event
1,000
  • earnings584
  • recall565
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Aug 11, 2025

    6
    ›Aug 14, 2025approval367d agoOTULFI (USTEKINUMAB-AAUZ) — FDA approvalOTULFI

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

    full page →OTULFI →fda approvals ↗
    ›Aug 14, 2025approval367d agoOTULFI (USTEKINUMAB-AAUZ) — FDA approvalOTULFI

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

    full page →OTULFI →fda approvals ↗
    ›Aug 14, 2025approval367d agoLAZCLUZE (LAZERTINIB MESYLATE) — FDA approvallazertinib mesylate

    Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

    full page →lazertinib mesylate →fda approvals ↗
    ›Aug 14, 2025approval367d agoRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalamivantamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →amivantamab →fda approvals ↗
    ›Aug 15, 2025approval366d agoBYOOVIZ (RANIBIZUMAB-NUNA) — FDA approvalBYOOVIZ

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →BYOOVIZ →fda approvals ↗
    ›Aug 15, 2025approval366d agoWEGOVY (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗

    Week of Aug 18, 2025

    15
    ›Aug 18, 2025approval363d agoKESIMPTA (OFATUMUMAB) — FDA approvalKESIMPTA

    Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →KESIMPTA →fda approvals ↗
    ›Aug 18, 2025approval

    Week of Aug 25, 2025

    5
    ›Aug 25, 2025approval356d agoOPUVIZ (AFLIBERCEPT-YSZY) — FDA approvalOPUVIZ

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →OPUVIZ →fda approvals ↗
    ›Aug 26, 2025approval

    Week of Sep 1, 2025

    24
    ›Sep 2, 2025approval348d agoEPYSQLI (ECULIZUMAB-AAGH) — FDA approvalEPYSQLI

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTION. Route: SOLUTION

    full page →EPYSQLI →fda approvals ↗
    ›Sep 3, 2025approval
    ← prev
    page 1 of 147
    next →
    363d ago
    BRIUMVI (UBLITUXIMAB-XIIY) — FDA approvalublituximab

    Sponsor: TG THERAPEUTICS, INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →ublituximab →fda approvals ↗
    ›Aug 18, 2025approval363d agoBRIUMVI (UBLITUXIMAB-XIIY) — FDA approvalublituximab

    Sponsor: TG THERAPEUTICS, INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →ublituximab →fda approvals ↗
    ›Aug 18, 2025approval363d agoTECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval(atezolizumab + hyaluronidase (human recombinant))

    Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INJECTION

    full page →(atezolizumab + hyaluronidase (human recombinant)) →fda approvals ↗
    ›Aug 18, 2025approval363d agoTECENTRIQ (ATEZOLIZUMAB) — FDA approvalatezolizumab

    Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INJECTION

    full page →atezolizumab →fda approvals ↗
    ›Aug 18, 2025approval363d agoVYEPTI (EPTINEZUMAB-JJMR) — FDA approvalH. Lundbeck AS

    Sponsor: Lundbeck Seattle BioPharmaceuticals, Inc.. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Aug 19, 2025approval362d agoTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalteclistamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →teclistamab →fda approvals ↗
    ›Aug 19, 2025approval362d agoTALVEY (TALQUETAMAB-TGVS) — FDA approvaltalquetamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →talquetamab →fda approvals ↗
    ›Aug 21, 2025approval360d agoIMCIVREE (SETMELANOTIDE ACETATE) — FDA approvalsetmelanotide

    Sponsor: RHYTHM. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →setmelanotide →fda approvals ↗
    ›Aug 21, 2025approval360d agoLEQEMBI (LECANEMAB-IRMB) — FDA approvallecanemab

    Sponsor: EISAI INC. Form: INJECTABLE. Route: INJECTION

    full page →lecanemab →fda approvals ↗
    ›Aug 21, 2025approval360d agoCEFAZOLIN SODIUM — FDA approvalSamson Medical Technologies LLC

    Sponsor: HIKMA FARMACEUTICA. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Aug 21, 2025approval360d agoCEFAZOLIN SODIUM — FDA approvalSamson Medical Technologies LLC

    Sponsor: HIKMA FARMACEUTICA. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Aug 21, 2025approval360d agoCEFAZOLIN SODIUM — FDA approvalSamson Medical Technologies LLC

    Sponsor: HIKMA FARMACEUTICA. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Aug 22, 2025approval359d agoVONJO (PACRITINIB CITRATE) — FDA approvalpacritinib

    Sponsor: SOBI. Form: CAPSULE. Route: ORAL

    full page →pacritinib →fda approvals ↗
    ›Aug 22, 2025approval359d agoVEKLURY (REMDESIVIR) — FDA approvalremdesivir

    Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS

    full page →remdesivir →fda approvals ↗
    355d ago
    TEPEZZA (TEPROTUMUMAB-TRBW) — FDA approvalteprotumumab

    Sponsor: HORIZON THERAPEUTICS IRELAND. Form: INJECTABLE. Route: INJECTION

    full page →teprotumumab →fda approvals ↗
    ›Aug 27, 2025approval354d agoFILSPARI (SPARSENTAN) — FDA approvalsparsentan

    Sponsor: TRAVERE. Form: TABLET. Route: ORAL

    full page →sparsentan →fda approvals ↗
    ›Aug 29, 2025approval352d agoBRIXADI (BUPRENORPHINE) — FDA approvalbuprenorphine LA

    Sponsor: BRAEBURN. Form: SOLUTION, EXTENDED RELEASE. Route: SUBCUTANEOUS

    full page →buprenorphine LA →fda approvals ↗
    ›Aug 29, 2025approval352d agoBILPREVDA (DENOSUMAB-NXXP) — FDA approvalBILPREVDA

    Sponsor: SHANGHAI HENLIUS BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →BILPREVDA →fda approvals ↗
    347d ago
    SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

    Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →risankizumab →fda approvals ↗
    ›Sep 3, 2025approval347d agoSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

    Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION

    full page →risankizumab →fda approvals ↗
    ›Sep 3, 2025approval347d agoVIGAFYDE (VIGABATRIN) — FDA approvalPyros Pharmaceuticals Inc.

    Sponsor: PYROS PHARMS. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Sep 3, 2025approval347d agoVIGAFYDE (VIGABATRIN) — FDA approvalPyros Pharmaceuticals Inc.

    Sponsor: PYROS PHARMS. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Sep 3, 2025approval347d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: RUBICON RESEARCH. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Sep 3, 2025approval347d agoRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalamivantamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →amivantamab →fda approvals ↗
    ›Sep 5, 2025grant345d agoEVOQUANT LLC — Leveraging Large Scale Bioinformatics and AI for Natural Product Drug Discove...

    AT grant. $306,872. PI: Chase Madison Clark

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoPERFUSION SOLUTIONS, INC. — A Fail Safe, High Output Failing Fontan Pump

    HL grant. $320,838. PI: WILLIAM A SMITH

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoUNIVERSITY OF CALIFORNIA LOS ANGELES — Understanding Mechanisms Driving Poor Outcomes in Women with DermatomyositisUniversity of California Los Angeles

    AR grant. $366,639. PI: Christina Charles-Schoeman

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoUNIVERSITY OF PENNSYLVANIA — Development of Dual-Action Nanoparticle-Loaded Microparticles for Osteoarthri...University of Pennsylvania

    AR grant. $646,506. PI: Zhiliang Cheng

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoBOSTON CHILDREN'S HOSPITAL — Mental and Behavioral Health Among Vulnerable Adolescents and Young Adults in...Boston Children's Hospital

    HD grant. $787,154. PI: Sabra L. Katz-Wise

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoUNIVERSITY OF ALABAMA AT BIRMINGHAM — Resource Core

    HD grant. $236,547. PI: Hui-Ju Young

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoSCRIPPS RESEARCH INSTITUTE, THE — in vivo modeling of IgH-reprogrammed B cells in mice

    HL grant. $647,573. PI: James Even Voss

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoUT SOUTHWESTERN MEDICAL CENTER — Project 2: Hepatocyte-targeted HCC chemoprevention with Anillin knockdown

    CA grant. $425,304. PI: Hao Zhu

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoUNIVERSITY OF PENNSYLVANIA — A mixed methods approach to understanding dementia caregiver stress when cari...University of Pennsylvania

    NR grant. $52,538. PI: Lauren Anne Fisher

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoUNIVERSITY OF CALIFORNIA, SAN FRANCISCO — Bridging the Gap Between Prediction and Reality in Structural BiologyUniversity of California San Francisco

    GM grant. $501,000. PI: James M Holton

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoUTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH — Integrating multi-omics data to understand the heterogeneity of preeclampsia ...University of Utah

    HL grant. $524,179. PI: Nathan Richard Blue

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoDUKE UNIVERSITY — Evaluating two novel, population-tailored health insurance designs: impact on...Duke University

    DK grant. $843,485. PI: James Franklin Wharam

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoWEILL MEDICAL COLL OF CORNELL UNIV — Graft Stiffness as a Substrate for Adverse Cardiovascular Remodeling and Clin...

    HL grant. $174,389. PI: Nupoor Narula

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoTUFTS UNIVERSITY MEDFORD — Pulse-oximetry method for un-biased assessment of arterial saturation

    HL grant. $134,537. PI: Giles Blaney

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoMEDICAL COLLEGE OF WISCONSIN — Evaluation of the influence of angiotensin type 1 receptor expression under d...

    DK grant. $49,538. PI: Gabriella Robilotto

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoLSU HEALTH SCIENCES CENTER — Kappa Opioid Receptor modulation of BLA inputs to the BNST and stress-escalat...

    AA grant. $337,500. PI: Rajani Maiya

    full page →nih reporter ↗
    ›Sep 5, 2025grant345d agoJOHNS HOPKINS UNIVERSITY — Investigating a novel vascular pathway that regulates neuronal survivalJohns Hopkins University

    AG grant. $480,710. PI: SHANTHINI SOCKANATHAN

    full page →nih reporter ↗
    $NVS150.88-0.55%
    $TGTX48.74+1.67%
    $TGTX48.74+1.67%
    $GILD138.36+0.16%
    $RYTM115.48-0.47%
    $TVTX62.14+1.16%
    $ABBV249.46-0.54%
    $ABBV249.46-0.54%